Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
• Trofinetide, an insulin-like growth factor 1 (IGF-1) analog, has shown neuroprotective effects.
• The therapeutic role of trofinetide in AD is not well understood.

Purpose of the Study:

• To investigate the therapeutic potential of trofinetide in Alzheimer's disease.
• To evaluate trofinetide's effects on cognitive function, amyloid pathology, neuroinflammation, and apoptosis in an AD mouse model.

Main Methods:

• APP/PS1 transgenic mice were treated with trofinetide.
• Cognitive function was assessed using the Morris water maze test.
• Amyloid pathology, microglial activation, neuronal loss, and molecular markers of inflammation and apoptosis were analyzed using immunohistochemistry, immunofluorescence, and Western blot.

Main Results:

• Trofinetide significantly improved cognitive deficits in APP/PS1 mice.
• Treatment reduced amyloid plaque deposition, microglial activation, and neuronal loss.
• In vitro studies showed trofinetide protected against amyloid-beta oligomer-induced cytotoxicity, suppressed inflammatory cytokines, and inhibited apoptosis.

Conclusions:

• Trofinetide demonstrates therapeutic potential for Alzheimer's disease.
• It mitigates key pathological hallmarks including Aβ pathology, neuroinflammation, and apoptosis.
• Further research into trofinetide as an AD therapeutic is warranted.